

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human EGF in direct ELISAs and Western blots. In direct ELISAs, approximately 30% cross-reactivity with recombinant rat EGF and approximately 15% cross-reactivity with recombinant mouse EGF is observed. Does not neutralize the biological activity of recombinant human TGF- $\alpha$ .
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Protein A or G purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human EGF Asn971-Arg1023 Accession # P01133
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 $\mu$ g/mL	Recombinant Human EGF (Catalog # 236-EG)
<b>Neutralization</b>		Measured by its ability to neutralize EGF-induced proliferation in the Balb/3T3 mouse embryonic fibroblast cell line. The Neutralization Dose (ND <sub>50</sub> ) is typically 1-3 $\mu$ g/mL in the presence of 2 ng/mL Recombinant Human EGF.

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 1 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Epidermal growth factor (EGF) is the founding member of the EGF family that also includes TGF- $\alpha$ , amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF-like growth factor (HB-EGF), epigen, and the neuregulins (NRG)-1 through -6 (1). Members of the EGF family share a structural motif, the EGF-like domain, which is characterized by three intramolecular disulfide bonds that are formed by six similarly spaced conserved cysteine residues (2). All EGF family members are synthesized as type I transmembrane precursor proteins that may contain several EGF domains in the extracellular region. The mature proteins are released from the cell surface by regulated proteolysis (1). The 1207 amino acid (aa) human EGF precursor contains nine EGF domains and nine LDLR class B repeats. The mature protein consists of 53 aa and is generated by proteolytic excision of the EGF domain proximal to the transmembrane region (3). Mature human EGF shares 70% aa sequence identity with mature mouse and rat EGF. EGF is present in various body fluids, including blood, milk, urine, saliva, seminal fluid, pancreatic juice, cerebrospinal fluid, and amniotic fluid (4). Four ErbB (HER) family receptor tyrosine kinases including EGFR/ErbB1, ErbB2, ErbB3 and ErbB4, mediate responses to EGF family members (5). These receptors undergo a complex pattern of ligand induced homo- or hetero-dimerization to transduce EGF family signals (6, 7). EGF binds ErbB1 and depending on the context, induces the formation of homodimers or heterodimers containing ErbB2. Dimerization results in autophosphorylation of the receptor at specific tyrosine residues to create docking sites for a variety of signaling molecules (5, 8). Biological activities ascribed to EGF include epithelial development, angiogenesis, inhibition of gastric acid secretion, fibroblast proliferation, and colony formation of epidermal cells in culture.

**References:**

1. Harris, R.C. *et al.* (2003) *Exp. Cell Res.* **284**:2.
2. Carpenter, G. and Cohen, S. (1990) *J. Biol. Chem.* **265**:7709.
3. Bell, G.I. *et al.* (1986) *Nucl. Acids Res.* **14**:8427.
4. Carpenter, G. and Zendegui, J.G. (1986) *Exp. Cell Res.* **164**:1.
5. Jorissen, R.N. *et al.* (2003) *Exp. Cell Res.* **284**:31.
6. Gamett, D.C. *et al.* (1997) *J. Biol. Chem.* **272**:12052.
7. Qian, X. *et al.* (1994) *Proc. Natl. Acad. Sci.* **91**:1500.
8. Qian, X. *et al.* (1999) *J. Biol. Chem.* **274**:574.